Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 55-59, 2020.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-781806
Biblioteca responsável:
WPRO
ABSTRACT
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action. We will also highlight the potential damage and the questions that are required to be answered.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2020
Tipo de documento:
Artigo